Literature DB >> 16509876

Clinicopathological features and medical management of intraductal papillary mucinous neoplasms.

Takehiro Okabayashi1, Michiya Kobayashi, Isao Nishimori, Takeki Sugimoto, Tsutomu Namikawa, Ken Okamoto, Nobuto Okamoto, Takuhiro Kosaki, Saburo Onishi, Keijiro Araki.   

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) are a clinicopathological entity that is being diagnosed with increasing frequency. However, the best approach to medical management of IPMN needs to be clarified. The aim of the present study was to identify preoperative features that may be predictors of malignant IPMN, and to define the medical management of IPMN of the pancreas.
METHODS: A total of 23 patients who underwent surgical resection for IPMN of the pancreas at Kochi Medical School between 1982 and 2004 were examined. Multivariate Cox regression analysis was used to identify factors independently associated with IPM carcinoma.
RESULTS: Among the 23 patients, 12 had IPMN adenoma, three had borderline IPMN, four had IPMN with carcinoma in situ, and four had IPMN with invasive carcinoma. In multivariate analysis, elevated serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 levels were found to be preoperative predictors of malignant IPMN. These results suggest that the following IPMN of the pancreas should be resected: (i) IPMN of the pancreas situated in the main duct; (ii) IPMN located in the branch duct if the size of the cystic lesion is >30 mm and the mural nodules are >5 mm in height by endoscopic ultrasound (EUS); and (iii) the diameter of the main pancreatic duct is >10 mm by endoscopic retrograde pancreatography (ERP). Careful observation of patients with branch-type IPMN with small cysts and/or without mural nodules is recommended as a management strategy.
CONCLUSION: The present study reinforces the need for immediate surgical resection of malignant IPMN and suggests indicators for IPMN that should assist physicians in making decisions on treatment options.

Entities:  

Mesh:

Year:  2006        PMID: 16509876     DOI: 10.1111/j.1440-1746.2005.03958.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  16 in total

Review 1.  Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas with Situs Inversus Totalis-Case Report with Review of Literature.

Authors:  Shailesh Mohandas; Richard Dickson-Lowe; Nariman Karanjia
Journal:  J Gastrointest Cancer       Date:  2012-09

Review 2.  Intraductal papillary mucinous neoplasms of the pancreas: making a disposition using the natural history.

Authors:  L William Traverso; Toshiyuki Moriya; Yasushi Hashimoto
Journal:  Curr Gastroenterol Rep       Date:  2012-04

3.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms.

Authors:  Paula Ghaneh; John Neoptolemos
Journal:  Gut       Date:  2007-08       Impact factor: 23.059

Review 4.  Endoscopic ultrasound advances, part 1: diagnosis.

Authors:  Edward Kim; Jennifer J Telford
Journal:  Can J Gastroenterol       Date:  2009-09       Impact factor: 3.522

5.  Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography.

Authors:  Hirofumi Harima; Seiji Kaino; Shuhei Shinoda; Michitaka Kawano; Shigeyuki Suenaga; Isao Sakaida
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

6.  Experience-based surgical approach to pancreatic mucinous cystic neoplasms with ovarian-type stroma.

Authors:  Chang Moo Kang; Akira Matsushita; Ho Kyoung Hwang; Yoko Matsuda; Hyunki Kim; Yoshiharu Nakamura; Woo Jung Lee
Journal:  Oncol Lett       Date:  2017-12-14       Impact factor: 2.967

7.  Natural history of intraductal papillary mucinous neoplasia: How much do we really know?

Authors:  Chad G Ball; Thomas J Howard
Journal:  World J Gastrointest Surg       Date:  2010-10-27

8.  Size of mural nodule as an indicator of surgery for branch duct intraductal papillary mucinous neoplasm of the pancreas during follow-up.

Authors:  Hiroyuki Uehara; Osamu Ishikawa; Kazuhiro Katayama; Natsuko Kawada; Kenji Ikezawa; Nobuyasu Fukutake; Rena Takakura; Yasuna Takano; Sachiko Tanaka; Akemi Takenaka
Journal:  J Gastroenterol       Date:  2010-11-18       Impact factor: 7.527

9.  Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience.

Authors:  Marco Niedergethmann; Robert Grützmann; Ralf Hildenbrand; Dag Dittert; Niloufar Aramin; Melanie Franz; Frank Dobrowolski; Stefan Post; Hans-Detlev Saeger
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

10.  Laparoscopic vs. open resection of noninvasive intraductal pancreatic mucinous neoplasms.

Authors:  Andrew A Gumbs; Philippe Grès; Fabio A Madureira; Brice Gayet
Journal:  J Gastrointest Surg       Date:  2007-10-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.